QSV Biologics (QSV), Ltd. Edmonton, Alberta, Canada, announced today that they have signed a contract with a biomedical company, Tissue Therapies Limited (ASX: TIS) for the process development and cGMP manufacture of clinical quantities of some of the therapeutic protein components of the VitroGro(R) platform for the accelerated healing of burns. cGMP means Current Good Manufacturing Practices - the quality level of production production required for human treatment. These are some of the essential components of the VitroGro(R) formulation that Tissue Therapies will use in a clinical trial later this year. Under the agreement, QSV will be responsible for technology transfer, process development, scaling up and cGMP production in QSV's manufacturing facility in Edmonton, Alberta. Terms of the final manufacturing contract remain confidential.
Tissue Therapies Limited is an Australian company developing biomedical technologies for wound healing, tissue regeneration and various cell culture applications.
Dr. Graeme Macaloney, QSV Founder & CEO said: "We are extremely please to be selected by Tissue Therapies to be their GMP manufacturer of choice for these components. The Tissue Therapies' management and technical team represent a top notch international organization developing a valuable therapeutic breakthrough for the treatment of burns and related conditions. Working with an Australian-based biopharmaceutical company represents a milestone for QSV in extending our global presence and underscores the benefit of the Health Canada Mutual Recognition Agreement with Australia and other jurisdictions like the European Union."
Dr. Steven Mercer, Tissue Therapies CEO said: "We are very happy to have established a commercial relationship with QSV for the supply of essential GMP components for our VitroGro(R) products. This agreement was the result of a careful international assessment of potential suppliers, with selection criteria including cGMP, technical and scientific experience, quality for production facilities and international health regulatory expertise. QSV impressed us in all these areas, particularly with their professionalism and scientific and regulatory expertise. We look forward to a long term, mutually beneficial relationship."
Dr. Mercer said, "This represents an important milestone in Tissue Therapies' progress towards our objective of the early release of approved products for burns and wound care, incorporating the VitroGro(R) platform."
About Tissue Therapies & QSV
Tissue Therapies, Ltd. The Company has worldwide exclusive rights to commercialise VitroGro(R), a platform technology developed by tissue engineering experts at the institute for Health and Biomedical Innovation at QUT for enhancing cell growth and migration. VitroGro(R) has particular commercial applications in wound healing, tissue regeneration and cell culture.
Based on its VitroGro(R) platform technology, Tissue Therapies is developing more effective medical treatments for wounds and burns, integration of orthopaedic and medical implants, and other applications such as cosmeceuticals.
Tissue Therapies also provides cell culture reagents to enhance the growth of mammalian cells for emerging cell-based therapies, along with research and industrial cell culture markets internationally.
For further information about Tissue Therapies and its products please visit their website at www.tissuetherapies.com.
QSV Biologics, Ltd., based in Edmonton, Canada, is one of an elite group of international cGMP biologics contract manufacturers providing mammalian cell culture and microbial fermentation services. QSV's market consists of global biotechnology firms with protein therapeutics in development. As a dedicated contract manufacturer, QSV provides cell banking, process & analytical development, technology transfer, scale up and pre-clinical through Phase III & early commercial manufacturing. QSV builds value for its clients by producing quality products in a timely manner. Hence its acronym: QSV: Quality and Speed build Value. More information can be obtained from www.gsvbiologics.com.
For further information: Richard Hetrick, Director of Business Development, QSV Biologics Ltd., (780) 438-7143